APLMW — Apollomics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1944885 ·
Last close
$0.01
Market Cap
—
52W High
$0.01
52W Low
$0.01
ADV30
6,208
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 6,714,000 | 3,276,000 | 9,902,000 |
| Jun 2025 | — | — | — | — | 11,119,000 | 2,094,000 | 15,517,000 |
| Dec 2024 | — | — | — | — | 13,098,000 | 9,766,000 | 8,234,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-711,762,000
Inventory
—
Receivables
$2,490,000
ST Investments
$0
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 8,500,000 | -9,194,000 | -10,939,000 | 6,714,000 | 9,902,000 | -3,188,000 | -10,369,000 |
| Dec 2024 | 0 | -42,033,000 | -53,858,000 | 13,098,000 | 8,234,000 | 4,864,000 | -28,743,000 |
| Dec 2023 | 0 | -54,370,000 | -172,601,000 | 55,387,000 | 14,153,000 | 41,234,000 | -43,209,000 |
| Dec 2022 | 0 | -44,388,000 | -240,811,000 | 76,475,000 | 524,595,000 | -448,120,000 | -42,824,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1184.78 | — |
| JNJ | JOHNSON & JOHNSON | $655.37B | $271.95 | — |
| ABBV | AbbVie Inc. | $470.55B | $266.28 | — |
| MRK | Merck & Co., Inc. | $366.84B | $148.69 | — |
| NVS | NOVARTIS AG | $279.18B | $146.88 | — |
News headlines (Yahoo Finance, 1h cache)
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
2026-07-13 12:00 · Yahoo
Apollomics Announces $10 Million Private Placement Transaction
2026-08-11 20:35 · Yahoo
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
2026-06-24 20:15 · Yahoo
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
2026-04-27 12:00 · Yahoo
Apollomics Inc. Announces $2.0 Million Bridge Financing
2026-04-01 11:00 · Yahoo
Apollomics Reports First Half 2025 Financial Results
2025-12-22 21:05 · Yahoo
Apollomics Announces Settlement of Cayman Litigation
2025-11-19 22:38 · Yahoo
Apollomics Announces Changes to its Board of Directors and Composition of Committees
2025-11-18 04:00 · Yahoo
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
2025-10-15 18:36 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.